The Prognostic Value of Baseline Distant Metastasis in Icotinib-Treated Patients with EGFR-Mutated Stage IV Non-Small Cell Lung Cancer
Long Wang,1,* Tiantian Shi,1,* Li Feng,1 Zhisong Fan,1 Xiaoli Xu,2 Xinliang Zhou,1 Xue Zhang,1 Jing Han,1 Li Jing,1 Jiayin Liu,1 Yujie Shan,1 Fengling Liu,1 Jing Zuo,1 Yudong Wang1 1Department of Medical Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, People&rsqu...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2021-03-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/the-prognostic-value-of-baseline-distant-metastasis-in-icotinib-treate-peer-reviewed-article-CMAR |
| _version_ | 1828925626508115968 |
|---|---|
| author | Wang L Shi T Feng L Fan Z Xu X Zhou X Zhang X Han J Jing L Liu J Shan Y Liu F Zuo J Wang Y |
| author_facet | Wang L Shi T Feng L Fan Z Xu X Zhou X Zhang X Han J Jing L Liu J Shan Y Liu F Zuo J Wang Y |
| author_sort | Wang L |
| collection | DOAJ |
| description | Long Wang,1,* Tiantian Shi,1,* Li Feng,1 Zhisong Fan,1 Xiaoli Xu,2 Xinliang Zhou,1 Xue Zhang,1 Jing Han,1 Li Jing,1 Jiayin Liu,1 Yujie Shan,1 Fengling Liu,1 Jing Zuo,1 Yudong Wang1 1Department of Medical Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, People’s Republic of China; 2Department of Medical Records, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yudong Wang Email 15931166600@126.comPurpose: Several studies have revealed the prognostic value distant metastasis in non-small-cell lung cancer (NSCLC) patients receiving first-line epidermal growth factor receptor (EGFR) inhibitors. However, the question of whether the specific metastatic site could predict survival outcomes remain elusive. This study evaluated the prognostic value of specific metastatic site at diagnosis in first-line icotinib-treated patients with EGFR-mutated advanced NSCLC.Methods: A total of 216 patients with EGFR-mutated stage IV NSCLC who received first-line icotinib treatment were retrospectively enrolled. The associations between the presence of distant metastasis to certain organs at diagnosis and survival outcomes were analyzed.Patients and methods: The presence of distant metastases was not associated with progression-free survival. Patients with liver metastasis showed a significantly shorter OS than those without liver metastasis (14.6m vs 33.0m, p=0.024). Patients with brain metastasis showed a marginally shorter OS than those without brain metastasis (26.5m vs 33.8m, p=0.051). Patients with lung metastasis showed a significantly longer OS than those without lung metastasis (36.0m vs 28.6m, p=0.038). Multivariable Cox regression analysis showed the presence of liver metastasis (HR [hazard ratio]: 2.265, 95% CI [confidence interval]: 1.239– 4.139, p=0.008) and brain metastasis (HR: 1.493, 95% CI: 1.012– 2.202, p=0.043) were independent predictors for unfavorable OS, while lung metastasis (HR: 0.669, 95% CI: 0.460– 0.971, p=0.034) was an independent predictor for favorable OS.Conclusion: The presence of liver and brain metastasis predicted unfavorable OS, while the presence of lung metastasis predicted favorable OS in first-line icotinib-treated patients with EGFR-mutated stage IV NSCLC.Keywords: metastasis, non-small cell lung cancer, EGFR mutations, icotinib, prognostic value |
| first_indexed | 2024-12-13T23:18:12Z |
| format | Article |
| id | doaj.art-cda148ca549b44f296adb870e5550e6c |
| institution | Directory Open Access Journal |
| issn | 1179-1322 |
| language | English |
| last_indexed | 2024-12-13T23:18:12Z |
| publishDate | 2021-03-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Cancer Management and Research |
| spelling | doaj.art-cda148ca549b44f296adb870e5550e6c2022-12-21T23:27:52ZengDove Medical PressCancer Management and Research1179-13222021-03-01Volume 132613262263210The Prognostic Value of Baseline Distant Metastasis in Icotinib-Treated Patients with EGFR-Mutated Stage IV Non-Small Cell Lung CancerWang LShi TFeng LFan ZXu XZhou XZhang XHan JJing LLiu JShan YLiu FZuo JWang YLong Wang,1,* Tiantian Shi,1,* Li Feng,1 Zhisong Fan,1 Xiaoli Xu,2 Xinliang Zhou,1 Xue Zhang,1 Jing Han,1 Li Jing,1 Jiayin Liu,1 Yujie Shan,1 Fengling Liu,1 Jing Zuo,1 Yudong Wang1 1Department of Medical Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, People’s Republic of China; 2Department of Medical Records, The Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yudong Wang Email 15931166600@126.comPurpose: Several studies have revealed the prognostic value distant metastasis in non-small-cell lung cancer (NSCLC) patients receiving first-line epidermal growth factor receptor (EGFR) inhibitors. However, the question of whether the specific metastatic site could predict survival outcomes remain elusive. This study evaluated the prognostic value of specific metastatic site at diagnosis in first-line icotinib-treated patients with EGFR-mutated advanced NSCLC.Methods: A total of 216 patients with EGFR-mutated stage IV NSCLC who received first-line icotinib treatment were retrospectively enrolled. The associations between the presence of distant metastasis to certain organs at diagnosis and survival outcomes were analyzed.Patients and methods: The presence of distant metastases was not associated with progression-free survival. Patients with liver metastasis showed a significantly shorter OS than those without liver metastasis (14.6m vs 33.0m, p=0.024). Patients with brain metastasis showed a marginally shorter OS than those without brain metastasis (26.5m vs 33.8m, p=0.051). Patients with lung metastasis showed a significantly longer OS than those without lung metastasis (36.0m vs 28.6m, p=0.038). Multivariable Cox regression analysis showed the presence of liver metastasis (HR [hazard ratio]: 2.265, 95% CI [confidence interval]: 1.239– 4.139, p=0.008) and brain metastasis (HR: 1.493, 95% CI: 1.012– 2.202, p=0.043) were independent predictors for unfavorable OS, while lung metastasis (HR: 0.669, 95% CI: 0.460– 0.971, p=0.034) was an independent predictor for favorable OS.Conclusion: The presence of liver and brain metastasis predicted unfavorable OS, while the presence of lung metastasis predicted favorable OS in first-line icotinib-treated patients with EGFR-mutated stage IV NSCLC.Keywords: metastasis, non-small cell lung cancer, EGFR mutations, icotinib, prognostic valuehttps://www.dovepress.com/the-prognostic-value-of-baseline-distant-metastasis-in-icotinib-treate-peer-reviewed-article-CMARmetastasisnon-small cell lung canceregfr mutationsicotinibprognostic value |
| spellingShingle | Wang L Shi T Feng L Fan Z Xu X Zhou X Zhang X Han J Jing L Liu J Shan Y Liu F Zuo J Wang Y The Prognostic Value of Baseline Distant Metastasis in Icotinib-Treated Patients with EGFR-Mutated Stage IV Non-Small Cell Lung Cancer Cancer Management and Research metastasis non-small cell lung cancer egfr mutations icotinib prognostic value |
| title | The Prognostic Value of Baseline Distant Metastasis in Icotinib-Treated Patients with EGFR-Mutated Stage IV Non-Small Cell Lung Cancer |
| title_full | The Prognostic Value of Baseline Distant Metastasis in Icotinib-Treated Patients with EGFR-Mutated Stage IV Non-Small Cell Lung Cancer |
| title_fullStr | The Prognostic Value of Baseline Distant Metastasis in Icotinib-Treated Patients with EGFR-Mutated Stage IV Non-Small Cell Lung Cancer |
| title_full_unstemmed | The Prognostic Value of Baseline Distant Metastasis in Icotinib-Treated Patients with EGFR-Mutated Stage IV Non-Small Cell Lung Cancer |
| title_short | The Prognostic Value of Baseline Distant Metastasis in Icotinib-Treated Patients with EGFR-Mutated Stage IV Non-Small Cell Lung Cancer |
| title_sort | prognostic value of baseline distant metastasis in icotinib treated patients with egfr mutated stage iv non small cell lung cancer |
| topic | metastasis non-small cell lung cancer egfr mutations icotinib prognostic value |
| url | https://www.dovepress.com/the-prognostic-value-of-baseline-distant-metastasis-in-icotinib-treate-peer-reviewed-article-CMAR |
| work_keys_str_mv | AT wangl theprognosticvalueofbaselinedistantmetastasisinicotinibtreatedpatientswithegfrmutatedstageivnonsmallcelllungcancer AT shit theprognosticvalueofbaselinedistantmetastasisinicotinibtreatedpatientswithegfrmutatedstageivnonsmallcelllungcancer AT fengl theprognosticvalueofbaselinedistantmetastasisinicotinibtreatedpatientswithegfrmutatedstageivnonsmallcelllungcancer AT fanz theprognosticvalueofbaselinedistantmetastasisinicotinibtreatedpatientswithegfrmutatedstageivnonsmallcelllungcancer AT xux theprognosticvalueofbaselinedistantmetastasisinicotinibtreatedpatientswithegfrmutatedstageivnonsmallcelllungcancer AT zhoux theprognosticvalueofbaselinedistantmetastasisinicotinibtreatedpatientswithegfrmutatedstageivnonsmallcelllungcancer AT zhangx theprognosticvalueofbaselinedistantmetastasisinicotinibtreatedpatientswithegfrmutatedstageivnonsmallcelllungcancer AT hanj theprognosticvalueofbaselinedistantmetastasisinicotinibtreatedpatientswithegfrmutatedstageivnonsmallcelllungcancer AT jingl theprognosticvalueofbaselinedistantmetastasisinicotinibtreatedpatientswithegfrmutatedstageivnonsmallcelllungcancer AT liuj theprognosticvalueofbaselinedistantmetastasisinicotinibtreatedpatientswithegfrmutatedstageivnonsmallcelllungcancer AT shany theprognosticvalueofbaselinedistantmetastasisinicotinibtreatedpatientswithegfrmutatedstageivnonsmallcelllungcancer AT liuf theprognosticvalueofbaselinedistantmetastasisinicotinibtreatedpatientswithegfrmutatedstageivnonsmallcelllungcancer AT zuoj theprognosticvalueofbaselinedistantmetastasisinicotinibtreatedpatientswithegfrmutatedstageivnonsmallcelllungcancer AT wangy theprognosticvalueofbaselinedistantmetastasisinicotinibtreatedpatientswithegfrmutatedstageivnonsmallcelllungcancer AT wangl prognosticvalueofbaselinedistantmetastasisinicotinibtreatedpatientswithegfrmutatedstageivnonsmallcelllungcancer AT shit prognosticvalueofbaselinedistantmetastasisinicotinibtreatedpatientswithegfrmutatedstageivnonsmallcelllungcancer AT fengl prognosticvalueofbaselinedistantmetastasisinicotinibtreatedpatientswithegfrmutatedstageivnonsmallcelllungcancer AT fanz prognosticvalueofbaselinedistantmetastasisinicotinibtreatedpatientswithegfrmutatedstageivnonsmallcelllungcancer AT xux prognosticvalueofbaselinedistantmetastasisinicotinibtreatedpatientswithegfrmutatedstageivnonsmallcelllungcancer AT zhoux prognosticvalueofbaselinedistantmetastasisinicotinibtreatedpatientswithegfrmutatedstageivnonsmallcelllungcancer AT zhangx prognosticvalueofbaselinedistantmetastasisinicotinibtreatedpatientswithegfrmutatedstageivnonsmallcelllungcancer AT hanj prognosticvalueofbaselinedistantmetastasisinicotinibtreatedpatientswithegfrmutatedstageivnonsmallcelllungcancer AT jingl prognosticvalueofbaselinedistantmetastasisinicotinibtreatedpatientswithegfrmutatedstageivnonsmallcelllungcancer AT liuj prognosticvalueofbaselinedistantmetastasisinicotinibtreatedpatientswithegfrmutatedstageivnonsmallcelllungcancer AT shany prognosticvalueofbaselinedistantmetastasisinicotinibtreatedpatientswithegfrmutatedstageivnonsmallcelllungcancer AT liuf prognosticvalueofbaselinedistantmetastasisinicotinibtreatedpatientswithegfrmutatedstageivnonsmallcelllungcancer AT zuoj prognosticvalueofbaselinedistantmetastasisinicotinibtreatedpatientswithegfrmutatedstageivnonsmallcelllungcancer AT wangy prognosticvalueofbaselinedistantmetastasisinicotinibtreatedpatientswithegfrmutatedstageivnonsmallcelllungcancer |